Hansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up

By Reuters News

** Shares of Hansoh Pharmaceutical 3692.HK jump 8.3% to HK$34.38, on course for biggest one-day pct gain since August 27

** Stock hits highest level since October 8, up for a third straight session

** China's Hansoh said on Monday it had entered into a partnership and licensing deal with Roche ROPC.S potentially worth more than $15 billion that covers a portfolio of antibody-drug conjugate programmes, which are targeted cancer therapies

** Under the terms of the partnership, Hansoh will lead early development until global Phase Ia clinical trials are complete. Roche will then take over worldwide development and commercialisation

** YTD, stock down 7%, while Hang Seng Biotech Index .HSBIO up 5.6%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.